Rapid Micro BiosystemsRPID
RPID
About: Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.
Employees: 163
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
276% more capital invested
Capital invested by funds: $10.8M [Q4 2024] → $40.4M (+$29.7M) [Q1 2025]
225% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 4
100% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 2 (+1) [Q1 2025]
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
47% more funds holding
Funds holding: 19 [Q4 2024] → 28 (+9) [Q1 2025]
7.86% more ownership
Funds ownership: 31.67% [Q4 2024] → 39.53% (+7.86%) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for RPID.
Financial journalist opinion
Neutral
GlobeNewsWire
2 days ago
Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LEXINGTON, Mass., June 13, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced the grants on June 2, 2025, of (i) 160,000 restricted stock units (“RSUs”) of the Company's Class A common stock (“Common Stock”) and (ii) non-qualified stock options to purchase an aggregate of 250,000 shares of Common Stock (the “Options”) as a material inducement to employment to a new employee. All such equity awards were made under the Company's Inducement Plan, as amended (the “Inducement Plan”) and were approved by a majority of the independent directors of the Board of Directors or a duly authorized committee thereof in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards are subject to the terms and conditions of the Inducement Plan, and the terms and conditions of the applicable stock option and RSU award agreements covering the grants.
Neutral
GlobeNewsWire
2 weeks ago
Rapid Micro Biosystems Announces Appointment of Dr. Dafni Bika to Board of Directors
LEXINGTON, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company” or “Rapid Micro”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to welcome Dr. Dafni Bika to the Company's Board of Directors (the “Board”).
Neutral
Seeking Alpha
1 month ago
Rapid Micro Biosystems, Inc. (RPID) Q1 2025 Earnings Call Transcript
Rapid Micro Biosystems, Inc. (NASDAQ:RPID ) Q1 2025 Earnings Conference Call May 9, 2025 8:30 AM ET Company Participants Mike Beaulieu - VP, IR and Corporate Communications Rob Spignesi - President and CEO Sean Wirtjes - CFO Conference Call Participants Dan Arias - Stifel Paul Knight - KeyBanc Capital Markets Chad Wiatrowski - TD Cowen Operator Thank you for standing by. My name is RG, and I will be your conference operator today.
Negative
Zacks Investment Research
1 month ago
Rapid Micro Biosystems, Inc. (RPID) Reports Q1 Loss, Tops Revenue Estimates
Rapid Micro Biosystems, Inc. (RPID) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.31 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Rapid Micro Biosystems Reports First Quarter 2025 Financial Results
LEXINGTON, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the first quarter ended March 31, 2025.
Neutral
GlobeNewsWire
1 month ago
Rapid Micro Biosystems to Announce First Quarter 2025 Financial Results on May 9, 2025
LEXINGTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release first quarter 2025 financial results prior to the market open on Friday, May 9, 2025.
Neutral
GlobeNewsWire
3 months ago
Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LEXINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced the grants (i) on March 3, 2025, of 50,000 restricted stock units (“RSUs”) of the Company's Class A common stock (“Common Stock”) as a material inducement to employment of one new employee and (ii) on March 10, 2025, of non-qualified stock options to purchase an aggregate of 250,000 shares of Common Stock (the “Options”) and 174,000 RSUs as a material inducement to employment to two new employees. All such equity awards were made under the Company's Inducement Plan, as amended (the “Inducement Plan”) and were approved by a majority of the independent directors of the Board of Directors or a duly authorized committee thereof in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards are subject to the terms and conditions of the Inducement Plan, and the terms and conditions of the applicable stock option and RSU award agreements covering the grants.
Neutral
Seeking Alpha
3 months ago
Rapid Micro Biosystems, Inc. (RPID) Q4 2024 Earnings Call Transcript
Rapid Micro Biosystems, Inc. (NASDAQ:RPID ) Q4 2024 Earnings Conference Call February 28, 2025 8:00 AM ET Company Participants Mike Beaulieu – Vice President, Investor Relations and Corporate Communications Rob Spignesi – President and Chief Executive Officer Sean Wirtjes – Chief Financial Officer Conference Call Participants Dan Arias – Stifel Paul Knight – KeyBanc Brendan Smith – TD Cowen Operator Thank you for standing by. My name is Eloisa, and I will be your conference operator today.
Negative
Zacks Investment Research
3 months ago
Rapid Micro Biosystems, Inc. (RPID) Reports Q4 Loss, Tops Revenue Estimates
Rapid Micro Biosystems, Inc. (RPID) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.26 per share a year ago.
Neutral
GlobeNewsWire
3 months ago
Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Guidance
LEXINGTON, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the fourth quarter and full year ended December 31, 2024.
Charts implemented using Lightweight Charts™